Page 117 - 2021_04-Haematologica-web

BET and FLT3 inhibition for FLT3-ITD AML
inhibitory activity (PIA): a pharmacodynam- ic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108(10):3477-3483.
23.Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123(1):94-100.
24. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS- like tyrosine kinase 3-internal tandem dupli- cation status. J Clin Oncol. 2013; 31(29):3681-3687.
25. Levis MJ, Cortes JE, Gammon GM, Trone D, Kang D, Li J. Laboratory and clinical investi-
gations to identify the optimal dosing strate- gy for quizartinib (AC220) monotherapy in FLT3-ITD-positive (+) relapsed/refractory (R/R) acute myeloid leukemia (AML). Blood. 2016;128(22):4042-4042.
26. Galanis A, Levis M. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica. 2015;100(3):e77-79.
27. Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-gen- eration FLT3 inhibitor. Blood. 2017; 129(2):257-260.
28. Chang YT, Hernandez D, Alonso S, et al. Role of CYP3A4 in bone marrow microenvi- ronment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. Blood Adv. 2019;3(6):908-916.
29.Berthon C, Raffoux E, Thomas X, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016; 3(4):e186-195.
30.
Amorim S, Stathis A, Gleeson M, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinet- ic, phase 1 study. Lancet Haematol. 2016; 3(4):e196-204.
31.McMahon CM, Ferng T, Canaani J, et al. Clonal selection with Ras pathway activa- tion mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050- 1063.
haematologica | 2021; 106(4)
1033